UChicago Obstetrics and Gynecology Department
@uchicago_obgyn
Official Twitter of the Department of #ObGyn at @UChicagoMed/@UCCancerCenter. Providing world-class obstetric and gynecologic care for all.
New from UChicago OB/GYN: Drs. Perinchery (PGY3) and Mills review sentinel lymph node mapping in vulvar and cervical cancers in @gynoncjnls, highlighting clinical evidence, surgical techniques and institutional insights. Read: sciencedirect.com/science/articl…


New in @UrogynJournal: Dr. Juraj Letko and colleagues highlight uterine preservation as a safe, effective option in prolapse surgery, supporting patient-centered, evidence-based care. Read: pubmed.ncbi.nlm.nih.gov/40168462/ #Urogynecology #PelvicHealth #PatientCenteredCare #UChicagoMed
🔥 Hot off the press: In a new @Nature study, @ErnstLengyel and team show that blocking NNMT in tumor-supporting cells restores immune response & stops ovarian cancer growth, offering a new strategy for hard to treat cancers. @OvCa_UChicago @uchicago_obgyn ow.ly/zzfZ50Wu3UW
Dr. Kimberly Kenton, Section Chief of Urogynecology at @UChicagoMed, delivered two invited presentations at #IUGAEUGA2025 in Barcelona: a plenary session on cancer & pelvic floor health, & a masterclass in robotic urogynecology. #PelvicHealth #Urogyn @iugaoffice

Meet our UChicago OB/GYN class of 2029 interns! Please join us in welcoming Drs. Jade Cook, Carin Caroll, Annika Brakebill, Julia DiNicola, Olivia Pruss, Cassidy Golden, Aishwarya Natarajan and Toni Madorsky. #OBGYN #Residency #Classof2029

Online Now: Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression dlvr.it/TLbW6y
New from the Lengyel/Kenny Lab: our study in @Cancer_Cell with @labs_mann charts how borderline ovarian tumors evolve into low-grade serous ovarian cancer, using spatial proteo-transcriptomics to uncover molecular drivers & potential therapeutic targets. sciencedirect.com/science/articl…
Join us in celebrating the UChicago OB/GYN Resident Class of 2025! Drs. Brockman, Byl, Hood, Hripko, Kar, Lamacki & Smith, thank you for your dedication to patient care, scholarship & leadership. We wish you all the best in the next chapter. #ResidencyGraduation




An interdisciplinary study @labs_mann & @uchicago_obgyn uncovers how benign borderline ovarian tumors develop into invasive low-grade serous carcinoma, opening a new avenue for targeted therapy. ❕Publication: cell.com/cancer-cell/fu… ❕Press Release: biochem.mpg.de/when-tumors-tu…
A new publication in @Cancer_Cell uncovers how borderline ovarian tumors evolve into low-grade serous ovarian cancer & identifies a promising new treatment strategy. Read: bit.ly/4luXCP8 @UCCancerCenter @LisaCSchweizer @hkenny228 @ErnstLengyel @labs_mann @MPI_Biochem


Our paper on ovarian cancer #LGSC is out in @Cancer_Cell. Using deep visual proteomics #DVP and spatial transcriptomics, we mapped how non-invasive tumors become deadly ovarian disease, and found a promising new treatment combination. cell.com/cancer-cell/fu…
From prenatal visits to postpartum care, UChicago Medicine midwives are here for every step. Learn more about the benefits of midwifery and how our expert team can help. uchicagomedicine.org/forefront/wome…
New study by Drs. Rivlin & Wascher in @jamanetworkopen: 42% of clinicians providing abortion practicing in ban states relocated post-Dobbs, most to states where abortion remains legal. These shifts threaten access to reproductive & maternal health care. ➡️bit.ly/3HCxnYh

Convocation 2025 is in the books. Here’s a look back at the sights and sounds from this year's celebration. #UChicago2025
New cover article in @CCR_AACR! Proteogenomic analysis reveals most synchronous endometrial & ovarian cancers (SEOC) arise from the uterus. @OvCa_UChicago @Mad_PhD @ErnstLengyel @labs_mann Read: bit.ly/4kVgq9L

The June 1 issue is online: aacrjournals.org/clincancerres/…
Sridevi Challa presented a poster on metabolic regulation of PARP inhibitor response in ovarian cancer cells #AACR25
New publication from Dr. Kenny et al. in Molecular Cancer Therapeutics! A novel 3-drug combo, navitoclax, YM155 & carboplatin, shows promise against chemoresistant ovarian cancer in preclinical models. @OvCa_UChicago @MCT_AACR Read: bit.ly/4dC2jUc

